Author Archives: admin

The Oncology Institute Reports First Quarter 2022 Financial Results and Confirms Full Year 2022 … – KULR-TV

By adminMay 12, 2022Stem Cell Clinic

CERRITOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial results for its first quarter ended March31, 2022.

"We are pleased with the results we achieved in Q1 2022, driven by our expansion in new markets and continued investment in a value-based approach to oncology. Our financial results reflected strong growth, with Q1 2022 revenue of $55 million, growing 14% compared to Q1 2021. We were thrilled to announce three new value-based partnerships in Q1 2022, one of which is with a new partner, MaxHealth in the Tampa and St. Petersburg markets, which has great potential for growth in the future, said Brad Hively, CEO of TOI. We also launched our 11th market in Polk County, Florida and opened a new clinic in Culver City, California as we continue to solidify our position in the Los Angeles market. We also recently announced our acquisition of Womens Cancer Care in Fresno, which will be our 12th market. We continue to strengthen our M&A pipeline which is expected to lead to positive growth throughout the rest of 2022. We are optimistic about the year ahead and continue to see strong partnership demand for our innovative model of oncology care."

First Quarter 2022 Operational Highlights

Initiated three new value-based partnerships, including our third gain share contract in Florida with MaxHealthHired five new clinicians, ending the period with 84 clinicians, representing a 24% growth compared to Q1 2021Commenced expansion of our radiation oncology site in Long Beach, California, added a new Radiation Oncology Medical Director and expanded our payor contractsOpened two new de novo clinics in Culver City, California and Polk County, Florida

First Quarter 2022 Results

Consolidated revenue for Q1 2022 was $55 million, a 13.5% increase compared to Q1 2021.

Revenue for the Patient Services segment was $35 million, up 18.3% compared to Q1 2021. Growth in Patient Services was driven by an increase in capitated contracts entered into in the latter half of 2021 as well as growth in FFS revenue due to practice acquisitions in Q4 2021 and an overall increase in clinic count. Dispensary revenue growth lagged the growth in Patient Services largely due to the Medical Rx transition. Despite the Medical Rx transition, dispensary revenue increased 6.0% compared to Q1 2021 due to an increase in the average revenue per script fill. Clinical Trials & Other revenue increased by 6.3% year-over-year due to an increase in clinical trials volumes.

Gross profit in Q1 2022 was $12 million, an increase of 20.8% compared to Q1 2021. The increase was driven by improved cost management of our oral and IV drugs and enhanced rebate opportunities.

SG&A expenses in Q1 2022 were $30 million or 54.0% of revenue, compared with $11 million, or 23.0% of revenue, in the same quarter last year. During Q1 2022, share-based compensation expense was $9 million and SG&A related to transaction costs was $1 million. The remainder of the SG&A growth was due to headcount and other costs associated with operating as a public company and to support revenue growth.

Net income for Q1 2022 was $19 million, increasing $20 million over the same quarter last year primarily due to the change in the fair value of the earnout liabilities. Adjusted EBITDA was $(5) million, a decrease of $5 million compared to Q1 2021, primarily as a result of our growth in SG&A as we prepare for expansion into new markets, as well as SG&A expenses necessary for TOI to operate as a public company.

2022 Outlook

Results for the first quarter of 2022 came in as expected and our outlook for 2022 remains unchanged.

(1) Adjusted EBITDA is a non-GAAP metric. See "Financial Information: Non-GAAP Financial Measures" below. TOI is not reasonably able to provide a reconciliation to net (loss) income due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including uncertainties regarding taxes, share-based compensation and other non-cash items. TOI expects interest expense in the range of $0.5 million and $1 million, other adjustment add backs in the range of $4 million and $6 million and depreciation and amortization in the range of $4 million and $6 million. TOI is not adding back new clinic startup or acquisition cost for this non-GAAP metric. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2022 adjusted EBITDA guidance is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. See "Forward-Looking Statements" below for additional information.

(2) Represents lives under capitation and gain sharing contracts. Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings with the SEC. The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our acquisitions, dispositions or financings during 2022. Our outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.

Webcast and Conference Call

TOI will host a conference call on Wednesday, May 11, 2022 at 5:00 p.m. (Eastern Time) to discuss first quarter results and managements outlook for future financial and operational performance.

The conference call can be accessed live over the phone by dialing 1-877-407-0789, or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13728629. The replay will be available until May 18, 2022.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of TOI's website at https://investors.theoncologyinstitute.com.

About The Oncology Institute, Inc.

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 80+ employed clinicians and more than 600 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit http://www.theoncologyinstitute.com.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as preliminary, believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, project, predict, potential, guidance, approximately, seem, seek, future, outlook, and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, anticipated financial results, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations of TOI and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by anyone as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of TOI. These forward-looking statements are subject to a number of risks and uncertainties, including the accuracy of the assumptions underlying the 2022 outlook discuss herein, the outcome of judicial and administrative proceedings to which TOI may become a party or governmental investigations to which TOI may become subject that could interrupt or limit TOIs operations, result in adverse judgments, settlements or fines and create negative publicity; changes in TOIs clients preferences, prospects and the competitive conditions prevailing in the healthcare sector; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on the TOIs business; those factors discussed in the documents of TOI filed, or to be filed, with the SEC, including the Item 1A. "Risk Factors" section of TOI's Annual Report on Form 10-K for the year ended December 31, 2021. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that TOI does not presently know or that TOI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect TOIs, plans or forecasts of future events and views as of the date of this press release. TOI anticipates that subsequent events and developments will cause TOIs assessments to change. TOI does not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing TOIs assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Financial Information; Non-GAAP Financial Measures

Some of the financial information and data contained in this press release, such as Adjusted EBITDA, have not been prepared in accordance with United States generally accepted accounting principles (GAAP). TOI believes that the use of Adjusted EBITDA provides an additional tool to assess operational performance and trends in, and in comparing our financial measures with, other similar companies, many of which present similar non-GAAP financial measures to investors. TOIs non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in TOI's financial statements. Because of the limitations of non-GAAP financial measures, you should consider the non-GAAP financial measures presented in this press release in conjunction with TOIs financial statements and the related notes thereto.

TOI defines Adjusted EBITDA as net (loss) income plus depreciation, amortization, interest, taxes, non-cash items, share-based comp and other adjustments to add-back the following: board fees, consulting and legal fees related to acquisitions, one-time consulting and legal fees related to certain advisory projects, software implementations and debt or equity financings, severance expense and temp labor and recruiting charges to build out our corporate infrastructure. A reconciliation of Adjusted EBITDA to net loss, the most comparable GAAP metric, is set forth below.

(1) During the three months ended March 31, 2022, non-cash addbacks were primarily comprised of bad debt write-offs of $154, non-cash rent of $29 and other miscellaneous charges of $14. During the three months ended March 31, 2021, non-cash addbacks were primarily comprised of a $13 tenant improvement allowance.

(2) Practice acquisition-related costs were comprised of consulting and legal fees incurred to perform due diligence, execute, and integrate acquisitions of various oncology practices.

(3) Consulting and legal fees were comprised of a subset of the Companys total consulting and legal fees during the three months ended March 31, 2022 and 2021, and related to certain advisory projects, software implementations, and legal fees for debt financing and predecessor litigation matters.

(4) Other, net is comprised of severance expenses resulting from cost rationalization programs of $18 and $0, as well as temporary labor of $485 and $223, recruiting expenses to build out corporate infrastructure of $424 and $155 and other miscellaneous charges of $26 and $0 during the three months ended March 31, 2022 and 2021, respectively. During the three months ended March 31, 2022 and 2021 such expenses were partially offset by $0 and $1,023, respectively, of stimulus funds received under the CARES Act.

(1) Includes independent oncology practices to which we provide limited management services, but do not bear the operating costs.

Condensed Consolidated Balance Sheets (in thousands except share data)

Condensed Consolidated Statements of Income (Operations) (Unaudited) (in thousands except share data)

Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

Contacts

Media The Oncology Institute, Inc. Julie Korinke juliekorinke@theoncologyinstitute.com (562) 735-3226 x 88806

Revive Michael Petrone mpetrone@reviveagency.com (615) 760-4542

Investors Solebury Trout investors@theoncologyinstitute.com

See the rest here:
The Oncology Institute Reports First Quarter 2022 Financial Results and Confirms Full Year 2022 ... - KULR-TV

ONCOLOGY INSTITUTE, INC. – 10-Q – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Insurance News Net

By adminMay 12, 2022Stem Cell Clinic

The following discussion and analysis provides information that managementbelieves is relevant to an assessment and understanding of the consolidatedresults of operations and financial condition of The Oncology Institute, Inc.("TOI") along with its consolidating subsidiaries (the "Company"). Thediscussion should be read together with the unaudited consolidated financialstatements and the related notes that are included elsewhere in this Report. Theinformation in this discussion contains forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended, and Section21E of the Securities and Exchange Act of 1934, as amended. Such statements arebased upon current expectations, as well as management's beliefs and assumptionsand involve a high degree of risk and uncertainty. Any statements containedherein that are not statements of historical fact may be deemed to beforward-looking statements. Statements that include the words "believes,""anticipates," "plans," "expects." "intends," and similar expressions thatconvey uncertainty of future events or outcomes are forward-looking statements.Our actual results could differ materially from those discussed or suggested inthe forward-looking statements herein. Factors that could cause or contribute tosuch differences include those described under the heading "Risk Factors" in ourAnnual Report on Form 10-K for the year ended December 31, 2021. In addition, asa result of these and other factors, our past financial performance should notbe relied on as an indication of future performance. All forward-lookingstatements in this document are based on information available to us as of thefiling date of this Quarterly Report on Form 10-Q and we assume no obligation toupdate any forward-looking statements or the reasons why our actual results maydiffer. All dollar values are expressed in thousands, unless otherwise noted.

Overview

Public Company Costs

Impact of COVID-19

Key Factors Affecting Performance

a recruiting process focused on selecting physicians that want to practice evidence-based medicine;

technology-enabled care pathways ensuring adherence to evidence-based clinical protocols;

strong clinical culture and physician oversight;

care delivered in community clinics versus hospital setting;

clinically appropriate integration of palliative care and hospice aligned with patients' goals for care;

access to clinical trials providing cutting-edge treatment options at low or no cost to patients or payors; and

appropriate provider training on clinical documentation to ensure proper risk adjustment and reimbursement for complex patients.

Key Business Metrics

$ 69

(1) Includes independent oncology practices to which we provide limited management services, but do not bear the operating costs.

The Company defines adjusted EBITDA as net income (loss) excluding:

Depreciation and amortization,

Changes in fair value of liabilities,

Stock-based compensation,

Practice acquisition-related costs,

Consulting and legal fees,

Public company transaction costs, and

Other specific charges.

The Company includes adjusted EBITDA because it is an important measure upon which our management uses to assess the results of operations, to evaluate factors and trends affecting the business, and to plan and forecast future periods.

Components of Results of Operations

Revenue

Capitation

Fee-for-service revenue

Clinical trials revenue

Dispensary cost

Dispensary cost primarily includes the cost of oral medications dispensed in the TOI PCs' clinic locations.

Selling, general and administrative expense

Results of Operations

Comparison of the Three Months Ended March 31, 2022 and 2021

Dispensary

Clinical trials & other

The increase in clinical trials and other revenue was primarily due to an increase in clinical trials volumes which were negatively impacted in the prior year due to the COVID-19 pandemic.

Dispensary cost

Selling, general and administrative expense

The decrease in interest expense was due to the pay-off of our term loan balance in Q4 2021.

Change in fair value of liabilities

Gain on debt extinguishment

Other, net

The change in other, net was primarily due to Provider Relief Funding under the CARES Act received during the three months ended March 31, 2021.

Liquidity and Capital Resources

General

Cash Flows

The following table presents a summary of the Company's consolidated cash flows from operating, investing, and financing activities for the periods indicated.

Cash and restricted cash at end of period $ 95,534 $ 27,412

Cash used by accounts payable, accrued expenses and income taxes payable increased $3,371 for the three months ended March 31, 2022 as compared to the three months ended March 31, 2021 primarily due to an increase in vendor payables due to the growth in the Company's business; and

Material Cash Requirements

Total material cash requirements $ 9,728 $ 14,264

$ 5,817 $ 2,505 $ 32,314

(1) Other is comprised of finance leases and directors and officers insurance premiums.

Leases

Variable Interest Entities

Segment Reporting

1.Identification of the contract, or contracts, with a customer.

2.Identification of the performance obligations in the contract.

3.Determination of the transaction price.

4.Allocation of the transaction price to the performance obligations in the contract.

5.Recognition of revenue when, or as, the entity satisfies a performance obligation.

Capitation

Fee For Service

Clinical Research

Direct Costs of Sales

Goodwill and Intangible Assets

Original post:
ONCOLOGY INSTITUTE, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations - Insurance News Net

Escargot controls somatic stem cell maintenance through the attenuation of the insulin receptor pathway in Drosophila – Newswise

By adminApril 29, 2022Somatic Stem Cells

Adultstem cellscoordinate intrinsic and extrinsic, local and systemic, cues to maintain the proper balance between self-renewal and differentiation. However, the precise mechanisms stem cells use to integrate these signals remain elusive. Here, we show that Escargot (Esg), a member of the Snail family of transcription factors, regulates the maintenance of somatic cyst stem cells (CySCs) in theDrosophilatestisby attenuating the activity of the pro-differentiationinsulin receptor(InR) pathway. Esg positively regulates the expression of an antagonist ofinsulin signaling,ImpL2, while also attenuating the expression ofInR. Furthermore, Esg-mediated repression of the InR pathway is required to suppress CySC loss in response to starvation. Given the conservation of Snail-family transcription factors, characterizing the mechanisms by which Esg regulates cell-fate decisions duringhomeostasisand a decline in nutrient availability is likely to provide insight into themetabolic regulationof stem cell behavior in other tissues and organisms.

Here is the original post:
Escargot controls somatic stem cell maintenance through the attenuation of the insulin receptor pathway in Drosophila - Newswise

A human accumulates as many mutations in 80 years as a mouse in its short life – EL PAS in English

By adminApril 29, 2022Somatic Stem Cells

Giraffes that weigh up to 1,200 kilograms accumulate as many mutations in their cells throughout their lives as naked mole-rats, which rarely weigh more than 35 grams. Similarly, living beings as long-lived as humans and as short-lived as rats reach the end of their days with a similar number of changes in the DNA of their cells. Recent research comparing different mammals shows that there is a kind of natural law that links the life expectancy of each species to mutagenesis. This connection could shed light on processes as complex as cancer or aging.

Since the 1950s, many scientists in the field have linked aging with various processes of cell deterioration. One such process is somatic mutation. These are genetic changes, between 20 and 50 a year in humans, that occur in the life cycle of the cell. They occur in healthy cells, although some of them can trigger tumors or other alterations. Occurring at the cellular level, somatic mutations should be related in some way to body mass and life expectancy. The reason why a correlation with the first would be expected is because in theory, the greater the mass, the greater the probability of cancer developing in some cell. On the other hand, if mutations play an important role in aging, they would theoretically have a connection to life expectancy. So researchers at the Wellcome Sanger Institute (United Kingdom) specialized in genomic research decided to study these genetic alterations in 16 species of mammals, looking for patterns that pointed to a common basis in the decline of life over time.

The research, published a few days ago in the journal Nature, is new for many reasons. One is because of its comparative analysis of species that differ significantly in size, life expectancy or diet. It is also new in its analysis of somatic mutations within cells, something impossible to do until very recently. It is also novel because of the object of its study: cells from a part of the colon (called intestinal crypts) that have the particularity that they all come from the same stem cell, making it possible to accurately calculate the number of mutations they contain. But, above all, it is new because of its findings, which may have implications for some of the fundamental questions about human health and other living beings.

If it depended only on the number of cells, a mouse would never develop a tumor... and you would expect all whales to die of colon cancer before the age of 30, simply because of their size

The main finding is that the number of mutations per year or mutation rate is adjusted to the life expectancy of each species. Although very diverse, this rate is inversely proportional to longevity. Thus, while humans, with their life expectancy of around 80 years, have an annual rate of 47 mutations in the cells of each intestinal crypt, mice, with a survival rate of only two years, suffer 796. At the end of their lifetime, all the animals under study accumulated a similar number of mutations. In addition, researchers found that three of the main mutagenesis processes identified, such as the substitution of one base for another in the sequence, are shared between the different species. So there is a connection between mutation and aging. Another very different thing is to know how that connection works.

Adrin Bez-Ortega is a researcher at the Wellcome Sanger Institute and, together with Alex Cagan, is the main author of this research. He cautions about connecting somatic mutations in the cell with the aging process of organisms. First, because we do not have data that would allow the results to be extended to other tissues beyond the colon. Second, because we have not studied it in other living beings that are not mammals. Even more importantly, they do not know the meaning of this relationship. We discovered a correlation between life expectancy and mutation rate, but we do not know if the mutation rate has evolved to adapt to the life expectancy of the animal or if the mutations affect this life expectancy, highlights the Spanish researcher. It is certain, he says, that there are other factors at play as well. For example, colon cells accumulate about 50 mutations a year, but suffer thousands of instances of cellular damage. These damages appear to also play a role in senescence.

The work confirms one of the most intriguing paradoxes in molecular biology. It was raised almost 50 years ago by the British epidemiologist Richard Peto. He observed that species were beyond logic in terms of the risk of suffering cancer. If tumors are the result of mutations or harmful changes at the cellular level, the more complex the cell, the more tumors there should be. But reality shows that the incidence of cancer in animals does not seem related to body mass. This new study confirms the so-called Peto paradox.

The incidence of cancer is similar between the species, even though they have differences in mass, notes Bez-Ortega. In general, larger animals tend to live longer. Since all cells have the same chance of developing cancer, the larger the cells, the greater the risk, one might think. But no. There is an incidence curve for cancer in humans that is known. If it depended only on the number of cells, a mouse would never develop a tumor, because it has far fewer cells and would not live long enough. Actually, they have an incidence similar to ours. And you would expect all whales to die of colon cancer before the age of 30, simply because of their size. But we see that evolutionary pressure has adjusted the rate of cancer, so that humans, elephants and mice have an almost identical curve once you control for their life expectancy. And we dont know why this happens, concludes the Spanish scientist.

The evolution of multicellular life requires carefully coordinating all cells so that each one plays exactly the right role in the organism. Somatic mutations can upset this balance

igo Martincorena heads research on somatic mutation in healthy and cancerous cells at the Wellcome Sanger Institute in the UK. He is also a senior author on the research published in Nature. Regarding the main findings of the work, he recognizes how intriguing it is. The evolution of multicellular life requires carefully coordinating all cells so that each one plays exactly the right role in the organism. Somatic mutations can upset this balance, as evidenced in the case of cancer, so the evolution of life has required controlling the accumulation of somatic mutations, he says in an email exchange. So the finding that the somatic mutation rate per year is much lower in species that live longer suggests that [these rates] are under evolutionary control.

Regarding the relationship between mutations and aging, Martincorena insists that senescence does not have a single cause. The most compelling hypothesis right now is that it is caused by the accumulation of various types of molecular damage in our cells, including somatic mutations, telomere shortening, protein aggregation, and epigenetic changes. We believe that these changes at the molecular level cause changes in our cells and tissues that give rise to the typical manifestations of aging. But whats not clear is how much each type of damage contributes. Our results suggest that somatic mutations probably contribute to aging to some extent, but exactly how much and in what way remains to be demonstrated, adds Martincorena, who concludes with an acknowledgment of the limitations of science: If there is still much understand in cancer, in aging our knowledge is still much more primitive.

Edited by S.U.

View original post here:
A human accumulates as many mutations in 80 years as a mouse in its short life - EL PAS in English

Student Opinion: Stem Cell Treatment Advances Towards A Brighter Future – The Peoples Vanguard of Davis

By adminApril 29, 2022Stem Cell Treatment

Cornea grafts can help to restore vision. Scientists in Japan are planning to graft tissue grown from stem cells. Credit: Burger/Phanie/Science Photo Library

By Kayla Ngai

Researchers at Osaka University led by Kohji Nishida, an ophthalmologist in Japan, were successfully able to treat corneal disease in four patients in a clinical trial that was provisionally approved in 2019. According to the Illinois Eye Center, Corneal disease is a serious condition that can cause clouding, distortion, scarring, and eventually blindness. Corneal disease is very common among the elderly, but quality tissue for corneal cells is rare to come by. I believe that Japan is making great efforts in medical advancements to help its aging population.

When CBS News covered this topic, they mentioned that the stem cell research was supposed to help cope with the worlds oldest population. However, in the article, they did not go into detail about Japans population. I feel that it is important to talk about Japans elderly because the trials and treatments would be mostly beneficial to them. For starters, a huge majority of Japans population is the elderly (being about 65 years or older). This means that their population is dwindling and many members of their society are suffering from degenerative diseases.

Due to the problems that arise with aging, taking care of the elderly has been difficult. The proportion of older people to the younger generation shows an imbalance, so theres a deficit of people that can care for the elders. Thus, many youths are also not able to work full time.

According to Japan Today, a study from a 2019 labor ministry report showed that about 40% of citizens were only working part-time or as temporary hires. On top of everything, after the pandemic hit, more people lost their jobs. The countrys economy grew unstable. As the middle class isnt making as much money, they are slowly [sink] into poverty. However, the use of stem cells for degenerative diseases may make it easier to take care of elders, as well as help the older generation gain more independence.

The researchers in the corneal disease study used stem cells grown in a lab which are basic building blocks that can be developed into other cells. Specifically, the stem cells that are utilized are induced pluripotent stem (iPS) cells that have been reverted back to the stem state so that they can serve as the building unit for most organ tissue. For the latest cornea study, three of the patients eyesight improved and have been reported with no side effects a year later. The Japanese government has invested $970 million towards iPS technology for regenerative medicine and the idea behind stem cell research is to raise artificial cells to replace the damaged or unhealthy ones in the body.

The iPS solution for corneal implants would be a stepping stone for other medical technologies. There are already discussions surrounding stem cells being used to help treat other disorders. For example, Toru Kimura, Representative Director and Executive Vice President of Sumitomo Dainippon Pharma, is currently working with Kyoto University on a solution to the neurodegenerative disease Parkinsons.

Although Japans population problem is a major concern, the use of iPS stem cells would be an effective way to mediate the issue. The research would make great strides forward not only for Japan but for other countries as well. If more trials go through, the elderly population wouldnt have to suffer as much from various degenerative diseases. They would no longer need as much assistance to look after themselves and the young can take full-time jobs. However, as iPS makes its way to being utilized in society, I think researchers need to find more information about the limitations of iPS and other stem cells.

Even though I think these advancements in medicine are a good thing that would help Japans economy and substantially benefit the elderly population living there, I am also a little skeptical about the long-term effects. For instance, there could be a risk for carcinogens, which are capable of causing cancer. Hence, as with all new medical developments, we need to be wary about the initial success. But for now, the trials attest to great promise!

See original here:
Student Opinion: Stem Cell Treatment Advances Towards A Brighter Future - The Peoples Vanguard of Davis

Cell Isolation/Cell Separation Market Size, Share, Prospects and Upcoming Trends 2021-2030 themobility.club – themobility.club

By adminApril 29, 2022Embryonic Stem Cells

Global Cell Isolation/Cell Separation MarketSize study, By Product (Consumables, Instruments), By Cell Type (Human Cells {Differentiated Cells, Stem Cells}, Animal Cells), By Cell Source (Bone Marrow, Adipose Tissue, Cord Blood/ Embryonic Stem Cells), By Technique (Centrifugation- Based Cell Isolation, Surface Marker- Based Cell Isolation, Filteration- Based Cell Isolation), By Application (Biomolecule Isolation, Cancer Research, Stem Cell Research, Tissue Regeneration & Regenerative Medicine, In Vitro Diagnostics), By End User (Biotechnology And Biopharmaceutical Companies, Hospitals And Diagnostic Laboratories, Research Laboratories And Institutes, Other End Users), and Regional Forecasts 2022-2028

Global Cell Isolation/Cell Separation Market is valued approximately USD 6.9 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 16.8% over the forecast period 2022-2028.

Request To Download Sample of This Strategic Report: https://www.quadintel.com/request-sample/cell-isolationcell-separation-market/QI037

Cell isolation is also known as cell separation which is a process of isolating one or more specific cell populations from the varied cell combinations. This process can be performed in a variety of intricate biological samples, such as whole peripheral blood and leukapheresis products. Cell separation is a significant component in many life sciences, from stem cell and oncology research to routine clinical diagnosis, thereby, these factors are augmenting the market growth. In addition, the increasing number of government funding for cell-based research, the rising prevalence of cancer and infectious diseases among the population, coupled with growing focus on personalized medicine are the major factors that are stimulating the market demand around the world.

For instance, according to the International Agency for Research on Cancer (IARC), in 2018, there were nearly 17.0 million new cancer cases were recorded and 9.5 million cancer deaths globally 2018. Additionally, the amount is anticipated to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. . However, ethical issues associated with embryonic stem cell isolation and the high cost of cell-based research impede the growth of the market over the forecast period of 2022-2028. Also, technological developments and innovation in cell isolation are anticipated to act as a catalyzing factor for the market demand during the forecast period.

The key regions considered for the globalCell Isolation/Cell Separation Marketstudy include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the availability of the well-established infrastructure for life science research and the presence of the leading market players. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the increasing number of technological developments, as well as the rising prevalence of cancer, would create lucrative growth prospects for the Cell Isolation/Cell Separation Market across the Asia-Pacific region.

DOWNLOAD FREE SAMPLE REPORThttps://www.quadintel.com/request-sample/cell-isolationcell-separation-market/QI037

Major market players included in this report are: Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Limited Beckman Coulter Inc. Terumo BCT GE Healthcare Bio- Rad Laboratories Inc. Corning Inc. Miltenyl Biotech pluriSelect Life Science Akadeum Life Sciences, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:Consumables Instruments

By Cell Type:Human Cells Differentiated Cells Stem Cells Animal Cells

By Cell Source:Bone Marrow Adipose Tissue Cord Blood/ Embryonic Stem Cells

By Technique:Centrifugation- Based Cell Isolation Surface Marker- Based Cell Isolation Filtration- Based Cell Isolation

By Application:Biomolecule Isolation Cancer Research Stem Cell Research Tissue Regeneration & Regenerative Medicine In Vitro Diagnostics

By End User:Biotechnology And Biopharmaceutical Companies Hospitals And Diagnostic Laboratories Research Laboratories And Institutes Other End Users

Directly Purchase the Complete GlobalCell Isolation/Cell SeparationMarket Research Report @https://www.quadintel.com/request-sample/cell-isolationcell-separation-market/QI037

By Region:North America U.S. Canada Europe UK Germany France Spain Italy ROE

Asia Pacific China India Japan Australia South Korea RoAPAC Latin America Brazil Mexico Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2018, 2019, 2020 Base year 2021 Forecast period 2022 to 2028

Target Audience of the Global Cell Isolation/Cell Separation Market in Market Study:

Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investors

Companies Mentioned

Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Limited Beckman Coulter Inc. Terumo BCT GE Healthcare Bio- Rad Laboratories Inc. Corning Inc. Miltenyl Biotech pluriSelect Life Science Akadeum Life Sciences, Inc.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.quadintel.com/request-sample/cell-isolationcell-separation-market/QI037

Table of Contents:

What aspects regarding the regional analysis Market are included in this report?

About Quadintel:

We are the best market research reports provider in the industry. Quadintel believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Quadintel is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Quadintel:Email:sales@quadintel.com Address: Office 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE) Website:https://www.quadintel.com/

See more here:
Cell Isolation/Cell Separation Market Size, Share, Prospects and Upcoming Trends 2021-2030 themobility.club - themobility.club

Sen. Orrin Hatch’s legacy tracks the GOP’s evolution on health – NPR

By adminApril 29, 2022Embryonic Stem Cells

Democratic Sen. Ted Kennedy ( left) and Republican Sen. Orrin Hatch teamed up on a series of landmark legislative health care achievements, such as the Ryan White program on AIDS treatment, the Americans with Disabilities Act, and the first major federal child care law. John Duricka/AP hide caption

When it comes to health policy, former Utah Republican Sen. Orrin Hatch, who died Saturday at age 88, leaves a complex legacy of major legislative achievements, changing positions, compromises and fierce opposition. In many ways, though, Hatch's evolution and leadership on health policy during his four decades in the U.S. Senate mirror that of the Republican Party.

When he came to Washington as a neophyte politician after an upset victory in 1976, Hatch was a conservative firebrand, one of the early leaders of the "New Right" bent on dismantling the federal welfare state and banning abortion. A former trial lawyer, the new senator had never before held public office.

But the election of Ronald Reagan in 1980 and the Republican takeover of the Senate that made Hatch chairman of the powerful Labor and Human Resources Committee (now the Health, Education, Labor and Pensions Committee) turned him into something of a pragmatist. That pragmatism, it should be noted, was somewhat forced: Even though Hatch was technically the chair, there were enough moderate Republicans on the panel to give the ranking Democrat, Massachusetts' Edward Kennedy, effective control over what could be passed by the committee.

So Hatch learned to compromise and to legislate. In 1984, he negotiated with liberal Rep. Henry Waxman, D-Calif., what is still referred to as the "Hatch-Waxman Act." It's better known as the law that allowed, for the first time, approval of generic copies of brand-name drugs. Although far from a panacea, it is still the single-biggest advance in the fight to rein in high drug prices.

When the Democrats took back the Senate after the 1986 elections, Kennedy became chairman of the committee and Hatch, the ranking Republican. The two teamed up on a series of landmark legislative achievements, from the Ryan White program on AIDS treatment and the Americans with Disabilities Act to the first major federal child care law. And while Hatch was a strong foe of national health insurance, he and Kennedy ultimately pushed through Congress in 1997 the bill to create the Children's Health Insurance Program, which provides low-cost health insurance for low-income families who don't qualify for Medicaid.

The stridently anti-abortion Hatch was outspoken about his support for federal funding for research on embryonic stem cells derived from aborted fetuses. "I think it's the ultimate pro-life position, because I believe being pro-life is not just caring for the unborn but caring for those who are living," he told NPR in 2007.

But like much of the Republican Party in Congress, Hatch returned to his conservative roots after the election of President Barack Obama in 2008. A supporter of the so-called individual mandate requiring people to have health insurance when it was the quasi-official GOP position in the early 1990s, Hatch became an outspoken foe. "Congress has never crossed the line between regulating what people choose to do and ordering them to do it," he said in 2010.

After moderate Utah Republican Sen. Robert Bennett was ousted in a primary in 2010 and replaced by conservative favorite Mike Lee, Hatch grew more conservative to win reelection in 2012. His final term in the Senate was marked by efforts to overturn the Affordable Care Act and further restrict abortion access. The devout Mormon, who in his spare time wrote lyrics for best-selling Christian music, even called the ACA "the stupidest, dumb-a** bill that I've ever seen. Now some of you may have loved it; if you do, you are one of the stupidest dumb-a** people I've ever met." He later apologized for the statement.

A former Kennedy aide, Jim Manley, told The Salt Lake Tribune that "no one epitomizes the rightward lurch of the Republican Party more than Sen. Hatch."

In one final twist, however, Hatch pushed as his successor the 2012 GOP presidential nominee, Mitt Romney. In just his first few years, Romney has become one of the most moderate Republicans in the chamber. That may prove to be Orrin Hatch's final legacy.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. It is an editorially independent operating program of KFF (Kaiser Family Foundation).

Go here to read the rest:
Sen. Orrin Hatch's legacy tracks the GOP's evolution on health - NPR

Global Regenerative Medicine Market To Be Driven By Increasing Clinical Trials During The Forecast Period Of 2021-2026 themobility.club -…

By adminApril 29, 2022Embryonic Stem Cells

The new report by Expert Market Research titled, GlobalRegenerative Medicine MarketReport and Forecast 2021-2026, gives an in-depth analysis of the global regenerative medicine market, assessing the market based on its segments like technology, applications, and major regions . The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/regenerative-medicine-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

The emergence ofstem celltechnology, the untapped potential of nanotechnology, the rise in prevalence ofchronicdiseases and trauma emergencies, advancements in monitoring devices andsurgicaltechnologies, the rise in incidence of degenerative diseases, and the scarcity of organs for transplantation are all factors driving the growth of this market. Over the forecast period, the market is expected to be driven by rise in modern technology. The market expansion is predicted to be supplemented by a greater focus on stem cells and an increase in R&D activity in emerging markets. The emerging countries are concentrating on technical improvements, which is predicted to promote worldwide market growth. However, the markets expansion is expected to be hampered by government regulations, operational inefficiency, and the high cost of regenerative medicine treatment.

Industry Definition and Major Segments

Regenerative medicine is a branch of tissue engineering and molecular biology concerned with the replacement and regeneration of human cells, tissues, and organs in order to restore normal function. Bone graft alternatives, osteoarticular diseases, dermatological, cardiovascular, central nervous system, and other conditions are all treated with regenerative medicine.

Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/regenerative-medicine-market

By technology, the market is divided into:

Based on applications, the industry can be divided into:

By region, the industry is categorised into:

Latest News on Global Regenerative Medicine Market@https://www.expertmarketresearch.com/pressrelease/regenerative-medicine-market

Market Trends

The high number of clinical trials, growing economic impact on regenerative medicine, emerging applications of gene therapy in regenerative medicine, increasing government and private sector funding to support the development of regenerative medicine, and technological advances in stem cell, tissue engineering, and nanotechnology are driving the global regenerative medicine market. The regenerative medicine market is also being fueled by an increase in strategic partnerships, which aid in the commercialisation of regenerative medicine. Another factor driving up demand for regenerative treatments is the rising prevalence of chronic diseases and hereditary disorders, along with degenerative diseases and bone and joint problems. The high cost of therapy and the regulatory difficulties relating to stem cells, tissues engineering, and regenerative medicine, could stymie the industrys expansion.

The global market was dominated by North America. This is due to the presence of a large number of key players in the United States. The high number of clinical trials in this region is due to the availability of advanced technology and the existence of research institutes working in the development of innovative treatments. Due to the increase of infrastructure and facilities to expedite stem cell research in the regions growing economies, Asia Pacific is expected to have the highest CAGR during the projected period. The Chinese government has approved many research projects involving human embryonic stem cells, encouraging scientists to investigate the cells clinical potential. These factors are expected to boost the market during the foreast period as well.

Key Market Players

The major players in the market are Novartis AG, Vericel, Integra Lifesciences, Mimedx Group, Stryker, Wright Medical, Spark Therapeutics, Osiris Therapeutics, Kite Pharma (Subsidiary of Gilead Sciences), and Organogenesis, among others. The report covers the market shares, capacities, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

Media Contact

Company Name: EMR Inc. Contact Person: Steven Luke, Corporate Sales Specialist U.S.A. Email:sales@expertmarketresearch.com Toll Free Number: +1-415-325-5166 | +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA City: Sheridan State: Wyoming Country: United States Website:https://www.expertmarketresearch.com

Also, CheckProcurement Intelligencewhich provides you with Infallible research solutions.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

GeneTether Therapeutics Inc. Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights – TheNewswire.ca

By adminApril 29, 2022Embryonic Stem Cells

Vancouver, British Columbia TheNewswire - April 28, 2022 GeneTether Therapeutics Inc., (together with its wholly-owned subsidiary GeneTether, Inc., GeneTether or the Company) (CSE:GTTX), an early-stage genetic medicine company focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome, announced today the filing of its audited financial statements for the fiscal year ending December 31, 2021 and reported on corporate highlights from 2021. All dollar amounts are presented in the United States dollar, unless otherwise noted. Complete financial statements along with related management and discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada, at http://www.SEDAR.com.

Commenting on the Companys progress, CEO Roland Boivin said, Were pleased with our ability to close our IPO in these difficult market conditions, and we now have the means to significantly advance our R&D plan. In addition to the work currently being done as part of our UC Davis and ZeClinics collaborations,we have initiated the development of strategic plans to generate in vitro and in vivo model systems for uromodulin kidney disease ( [ANNOTATION:

BY 'Keith C. Inman' ON '2022-04-21T12:52:00'KCI NOTE: 'Consider using "uromodulin" and "kidney disease" instead of abbreviated terms']UMOD) with a focus on developing our lead therapeutic in ADTKD. Were also exploring collaboration opportunities with other genetic medicine companies as we believe our GeneTetherTM platform applies to most gene correction/gene complementation strategies, regardless of organ or disease.

R&D and Intellectual Property:

GeneTether achieved significant R&D progress in 2021, as the Company continues to develop best-in-class gene editing therapies based on its proprietary GeneTether platform:

In April 2021, GeneTether initiated an R&D program with ZeClinics of Barcelona, Spain, whereby ZeClinics will conduct a series of experiments in zebrafish embryos to, among other things, demonstrate the editing efficiency and toxicity of gene editing constructs incorporating the GeneTetherTM platform technology versus identical gene editing constructs without the GeneTetherTM platform technology.

In May 2021, GeneTether initiated an R&D program with the University of California, Davis (UCD) whereby researchers at UCD and members of GeneTethers R&D team will conduct a series of experiments in large animal eggs, embryos and embryonic stem cells to, among other things, demonstrate the editing efficiency of the GeneTetherTM platform technology versus identical gene editing constructs without the GeneTetherTM platform technology.

Between October 2021 and March 2022, GeneTether engaged in collaboration discussions with multiple genetic medicines companies based in Cambridge, Massachusetts. Those discussions are ongoing as of the date of this news release.

On February 9, 2022, the Company announced that the United States Patent and Trademark Office issued a Notice of Allowance with respect to a patent entitled Modified Nucleic Acid Editing Systems for Tethering Donor DNA related to its GeneTetherTM platform technology.

Board of Directors, Management, and Advisors

The Company succeeded in attracting high quality management team members and established its Scientific Advisory Board in 2021, creating a best-in-class team within gene therapy:

In January 2021, Mr. Andre Pereira Fraga Figueiredo and Mr. Daren Graham were elected to GeneTethers Board of Directors. Mr. Fraga has over 20 years of experience in MA, strategy, and business development in the petrochemical and renewable energy sectors, and is an active investor in early stage life science companies. Mr. Graham has nearly 20 years of experience in the life science industry as a merchant banker, senior operations executive, and corporate finance attorney. In April 2021, GeneTethers board of directors appointed Mr. Graham as its Chairperson.

In March 2021, the Company engaged Green BCN Consulting Services, a group of Barcelona-based consultants specializing in life science research, drug discovery and development, and strategic planning. Also in March 2021, Dr. Peter Sampson joined the Company as Vice President, Research and Development on a consulting basis. Dr. Sampson has over 20 years of experience in the life science industry, ranging from early-stage research and development to clinical trials.

In October 2021, Mr. Roland Boivin joined GeneTether as its Chief Executive Officer. Mr. Boivin has nearly 25 years of public company leadership experience, with a focus on strategic operations, finance, business development, and general management, including as CFO for Medexus Pharmaceuticals. GeneTethers shareholders also elected Mr. Boivin to the Board of Directors.

In October 2021 Ms. Jean Jen joined GeneTether as its Chief Financial Officer. Ms. Jen has over twelve years of finance and accounting experience, working with both private and public companies in the life sciences industry and in the gene-therapy space, including Nasdaq-listed Arbutus Biopharma Corporation.

In October 2021, GeneTethers Mr. P. Gage Jull jointed the Companys Board of Directors. Mr. Jull is Executive Chairman of Arrow Exploration Corp., a TSX-V listed oil and gas company active in Canada and Colombia. Mr. Jull was also a Co-Founder and Chairman of Bordeaux Capital Inc., a Toronto-based mergers and acquisitions advisory firm focused on emerging companies in the natural resources and other sectors. Mr. Jull is also a director of Tryp Therapeutics Inc. where he is the Chair of the board of directors and Audit Committee.

In October 2021, Dr. Kuldeep Neote joined GeneTether as the Chairperson of its Scientific Advisory Board. GeneTether also engaged Dr. Neote as a consultant for certain of its innovation and strategy activities. Dr. Neote earned his PhD in Molecular Genetics at the University of Toronto. He has over 25 years in the life science industry, including as a researcher at Genentech, Pfizer, and Eli Lilly and Company, and as a business development executive at Johnson Johnson and Eli Lilly and Company. He is currently an Entrepreneur-in-Residence at FACIT/OICR in Toronto and at The National Institutes of Health in Maryland.

Financing and Corporate Restructure

The Company succeeded in completing multiple financings and a corporate reorganization (the Reorganization) to support the ongoing development of its research and development activities:

From February to July 2021, GeneTether conducted a seed round private placement financing for aggregate proceeds of approximately US$1,000,000.

On November 30, 2021, the Company and GT Inc. completed the Reorganization, pursuant to which GeneTether Inc. became a wholly-owned subsidiary of the Company.

On March 29, 2022, the Company announced that it closed its initial public offering and concurrent private placement of units of the Company (the Units) for aggregate gross proceeds of C$4,500,000 at a price of C$0.60 per Unit. Each Unit was comprised of one common share in the capital of the Company (a Common Share), and one Common Share purchase warrant (a Warrant). Each Warrant entitles the holder to acquire one additional Common Share at an exercise price of C$0.72/share until March 29, 2025.

Financial Results

The Companys total assets as at December 31, 2021 were approximately $370,500, including approximately $180,000 in cash. Net and comprehensive loss for the twelve months ended December 31, 2021 were approximately $1,638,000.

About GeneTether

Founded by EGB Ventures founder and managing partner, William J. Garner, M.D., and veteran gene editing researcher, R. Geoffrey Sargent, Ph.D., GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies. The Companys wholly-owned platform technology uses a proprietary method to tether donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. The Company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases. GeneTethers proof of concept study demonstrated an approximately 7x higher gene editing efficiency as compared to the same gene editing payload without application of GeneTethers technology.

For more information, visitwww.genetether.com.

Contacts:

Roland Boivin, CEO

(833) 294-4363 ext. 1

roland@genetether.com

Jean Jen, CFO and Corporate Secretary

(833) 294-4363 ext. 2

jean@genetether.com

Forward-Looking Disclaimer

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause GeneTethers actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward-looking statements in this document include the expectation that the Company will significantly advance its research and development plan, expectations that the Company will develop collaboration opportunities with other genetic medicines companies, the expectation that the GeneTetherTM platform technology applies to most other gene correction/gene complementation strategies regardless of organ or disease, and all other statements that are not statements of historical fact.

Although GeneTether believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic; general economic conditions; adverse industry events; future legislative and regulatory developments; the Companys ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of GeneTether to implement its business strategies; competition; the ability of GeneTether to obtain and retain all applicable regulatory approvals and other assumptions, risks and uncertainties, including those set forth under the heading Risk Factors in the Companys final prospectus dated March 21, 2022.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

The Canadian Securities Exchange nor its Regulation Service has approved nor disapproved the contents of this news release

NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

The rest is here:
GeneTether Therapeutics Inc. Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights - TheNewswire.ca

Global Cell Counting Market to be Driven by the Increasing Demand in Hospitals and Diagnostic Laboratories in the Forecast Period of 2021-2026 …

By adminApril 29, 2022Embryonic Stem Cells

The new report by Expert Market Research titled,GlobalCell Counting MarketReport and Forecast2021-2026, gives an in-depth analysis of theglobal cell counting market, assessing the market based on its segmentslikeproduct type, end use,andmajor regions. Thereport tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along withanalysingthe market based on the SWOT and Porters Five Forces models.

Note 1: For a snapshot of the primary and secondary data of the market (2016-2026), along with business strategies and detailed market segmentation, please click on request sample report. The sample report shall be delivered to you within 24 hours.

Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/cell-counting-market/requestsample

The keyhighlights of the report include:

Market Overview (2016-2026)

During the projection period, hospitals and diagnostic laboratories are estimated to observe significant growth. This can be attributed to an increase in capital expenditure for the development of cell culture-based vaccines and the rapid expansion of the pharmaceutical industry. The rising prevalence of various chronic ailments, such as cancer, HIV-AIDS, leukaemia, Alzheimers, etc., is propelling the demand for cell counting techniques. The growing adoption of cell counting instruments across diverse medical fields, such as molecular biology, immunology, pathology, etc., for developing next-generation therapeutics is also augmenting the market growth. In addition to this, the increasing utilisation of cell counting for the identification and determination of primary tumours, circulating tumours, and metastatic tumour is further bolstering the market growth. The widespread adoption of stem cell therapy is also propelling the demand for various cell counting instruments on a global level.

Industry Definition and Major Segments

Cell counting refers to a technique used to analyse the cells or micelles that are usually suspended in blood or other body fluids. Some of the standard instruments used for cell counting includes hemocytometers, spectrophotometers, flow cytometers, and automated cell counters, among others. Cell counting aids in classifying cell types and detecting disease through probes to develop the best treatment plan for the patient. It also helps in understanding the structure and composition of the cells for chromosome analysis, protein expression, cancer diagnosis, and haematological malignancies, among others.

Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/cell-counting-market

By product type, the industry is segmented into:

The market can be broadly categorised on the basis of end use into:

On the basis ofregion, the industry is divided into:

Market Trends

The rising awareness of numerous benefits of cell counting techniques in immunophenotyping, cell sorting, cell proliferation assays, and intracellular calcium flux is further driving the market growth. The increasing investments by several government bodies in extensive research and development activities pertaining to the fields of biotechnology, oncology stem cell therapeutics, etc., are also bolstering the adoption of cell counting techniques. The presence of an array of medical research and biopharmaceutical businesses is anticipated to drive market growth in the coming years. With the rapid technological advancements, the market is predicted to be driven by innovations in existing products as well as the launch of new data visualisation and analysis tools. The market growth can also be associated with the increase in the number of proteomics and genomics researchers.

Key Market Players

The major players in the marketareThermo Fisher Scientific Inc.,Becton, Dickinson and Company,Bio-Rad Laboratories, Inc.,Beckman Coulter, Inc.,and PerkinElmer Inc.,among others.The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.